What Are the Options When No Matched Unrelated Donor Is Available?
When a bone marrow or stem cell transplant is medically indicated but no matched unrelated donor can be found in the registry, families often feel the search has reached a dead end. It has not. Several well-established donor alternatives exist — and for many patients, proceeding with a haploidentical (half-matched) family member as donor is not a compromise, but a primary strategy with decades of published outcomes data.
This article covers the following alternatives to a matched unrelated donor:
- Haploidentical (half-matched) family donor — parent, sibling, or adult child
- Cord blood transplant — from a public bank, including combined haplo + cord blood strategies
- Mismatched unrelated donor (MMUD) — 7/8 or 8/10 HLA match with modern GvHD prevention
- Extended and ethnicity-specific registry search — when time permits
- How to decide which alternative to pursue — and when disease urgency changes the calculus
Why Are Some Patients Unable to Find a Matched Unrelated Donor?
Identifying a fully matched unrelated donor (MUD — typically a 10/10 HLA match) through public registries is not possible for every patient. Understanding why a search may fail is the starting point for choosing the right alternative.
Ethnic background and registry representation
Stem cell donor registries — including DKMS, NMDP/Be The Match (USA), Anthony Nolan (UK), and others — are predominantly composed of donors of European descent. Patients from South Asian, East Asian, African, Middle Eastern, and mixed ethnic backgrounds have substantially lower probabilities of finding a fully matched unrelated donor. For patients from some backgrounds, the probability of a 10/10 MUD match may be below 30%.
Unusual or rare HLA type
Even within well-represented ethnic groups, some HLA combinations are rare enough that no matching donor exists in any global registry. This is independent of registry size — it reflects the biological diversity of HLA typing.
Disease urgency makes the search timeline unacceptable
A comprehensive international unrelated donor search — from initiation to donor confirmation, full evaluation, and harvest — takes a minimum of three to six months. For patients with rapidly progressive or relapsed disease, this timeline may not be clinically acceptable. Waiting for a registry match at the cost of disease progression may reduce the chance of a successful transplant outcome.
Registry search has already been completed and failed
Some families reach us after an extended search has been completed — no suitable donor identified across multiple registries. For these families, alternative donor strategies are no longer a theoretical discussion but an immediate clinical need.
The Main Donor Alternatives When No Matched Unrelated Donor Is Available
Haploidentical (Half-Matched) Family Donor
Usually the primary alternative — and often the first to evaluate
A haploidentical donor shares approximately 50% of HLA antigens with the patient — half the degree of matching of a fully matched donor. Critically, every patient has potential haploidentical donors among close relatives: both biological parents are haploidentical donors for their child; siblings have a 50% probability of being haploidentical; adult children are haploidentical donors for a parent.
This means donor availability is essentially guaranteed for patients with living close relatives — regardless of ethnic background and regardless of whether a registry match exists. The principal challenge of haploidentical transplant — managing the significantly increased risk of severe graft-versus-host disease (GvHD) from the HLA mismatch — has been addressed by two major protocol approaches:
Beijing Protocol (China)
Developed at Peking University Institute of Haematology. Uses G-CSF-mobilised peripheral blood stem cell (PBSC) plus bone marrow (BM) combined graft, with ATG-based GvHD prophylaxis. Supports combined graft strategies — PBSC with cord blood (CB) or mesenchymal stem cells (MSCs). Extensively published with large cohort outcome data. Now applied in 56% of all Chinese paediatric transplants nationally (CCBMTR 2017–2024 data).
PTCy Approach (Baltimore/Hopkins)
Uses post-transplant cyclophosphamide (PTCy) to selectively eliminate alloreactive T cells after graft infusion, dramatically reducing GvHD. Originally developed using bone marrow grafts. Now widely adopted internationally and increasingly used with PBSC grafts. Particularly well-studied in adult recipients and is the predominant Western approach to haploidentical transplant.
For several major transplant indications — including acute leukaemia, aplastic anaemia, and thalassaemia major — published data from multiple centres show outcomes with haploidentical donors that are comparable to, and in some analyses equivalent to, matched unrelated donor transplant. This is a fundamental shift from a decade ago, when haploidentical transplant was considered a last resort.
China's haploidentical transplant programme has accumulated the world's largest published experience with this approach. For international families facing donor shortage, this is one of the most concrete clinical reasons to seek a Chinese specialist review.
Cord Blood Transplant
Particularly relevant for smaller/paediatric patients; certain indication-specific advantages
Umbilical cord blood (CB) stored in public banks does not require the same degree of HLA matching as adult unrelated donor transplant. A 4/6 or 5/6 HLA match may be acceptable, which substantially increases the probability of finding a suitable unit — including for patients from underrepresented ethnic backgrounds.
Single cord blood unit: Appropriate for smaller patients (typically paediatric) where cell dose from a single unit meets the minimum threshold. Cell dose (total nucleated cells/kg recipient body weight) is the primary limiting factor.
Double cord blood transplant: Two cord blood units infused together to achieve adequate cell dose for larger patients. One unit typically predominates long-term. Higher risk of graft failure and delayed engraftment than haploidentical transplant in most analyses.
Combined haplo + cord blood (China): A Chinese innovation. Haploidentical PBSC provides rapid engraftment; cord blood unit provides T cell reconstitution and potential GvL (graft-versus-leukaemia) effect. Used in approximately two-thirds of haploidentical PBSC transplants in Chinese paediatric practice (CCBMTR data). Particularly studied in metabolic diseases (IEM): cord blood from an unrelated donor may deliver higher enzyme levels than a related haploidentical donor.
Cord blood transplant is not appropriate for all indications. It is most commonly used in paediatric patients and in specific conditions — such as inherited metabolic diseases, certain immune deficiency syndromes, and cases where cord blood's graft-versus-leukaemia effect is advantageous. Indication-specific guidance is part of any structured transplant evaluation.
Mismatched Unrelated Donor (MMUD)
7/8 or 8/10 HLA match — now more viable with modern GvHD prevention protocols
A mismatched unrelated donor shares most but not all HLA antigens with the patient — typically a 7/8 or 8/10 match. Historically this was associated with substantially higher GvHD risk than fully matched transplant. Modern PTCy-based protocols have significantly improved MMUD outcomes, making a single antigen-mismatched unrelated donor a reasonable strategy at experienced centres.
Extended and Ethnicity-Specific Registry Search
Appropriate when time permits; often run concurrently with evaluation of family donors
If a patient's initial domestic registry search fails, expanding to international registries — through BMDW (Bone Marrow Donors Worldwide), DKMS, Anthony Nolan, ABMDR — increases the pool of potential donors. For specific ethnic groups, targeted registries may offer better representation. For example, Gift of Life serves the Ashkenazi Jewish community; ABMDR has specific South Asian donor programmes.
Registry searches and family donor evaluation are typically run in parallel, not sequentially. Waiting for a complete registry search before evaluating family donors can cost weeks to months of preparation time that may be clinically significant. In most cases, the treating transplant team should be simultaneously identifying family donor candidates and initiating or continuing the registry search.
Family told no matched donor is available?
A structured case review with Chinese haematology and transplant specialists can evaluate haploidentical family donors, assess cord blood options, and provide a concrete recommendation — before any travel decision is made.
Request a case reviewHow Do Doctors Decide Which Alternative Donor Strategy to Use?
No single factor determines which alternative donor approach is most appropriate. The following are the key variables that a transplant MDT considers together:
Disease urgency and time pressure
The most critical variable. For a patient with rapidly progressive or relapsed leukaemia, waiting three to six months for a registry match may not be acceptable. A haploidentical family donor — available immediately — may allow transplant to proceed at the optimal disease status. Disease status at the time of transplant is one of the strongest predictors of outcome.
Indication and disease type
Some indications have indication-specific evidence for particular donor types. Aplastic anaemia: haploidentical with cyclophosphamide-based conditioning is well-validated. Thalassaemia major: haploidentical outcomes at experienced centres are now comparable to matched donors (>90% FFS). Inherited metabolic diseases: cord blood (especially unrelated CB) may deliver higher enzyme activity than a related haploidentical donor. JMML: haploidentical with specific conditioning is supported by published data.
Patient size and age
Cord blood cell dose scales with patient body weight. For larger patients (typically adults or older adolescents), cord blood cell dose from a single unit may be insufficient, making haploidentical or combined haplo+CB strategies more appropriate. Paediatric patients are better candidates for single-unit cord blood.
Available family donors and their fitness
The number and health status of available family donors matters. Most patients have two potential parent donors and potentially adult siblings or children. Donor age (younger donors generally preferred), donor health, and the specific HLA mismatches between patient and donor all affect selection. Evaluating all potential family donors simultaneously is more efficient than evaluating them sequentially.
Centre experience
Outcomes with alternative donor transplant depend substantially on centre experience — specifically the number of cases performed with each approach and the specific protocols used. This is particularly true for haploidentical transplant, where protocol selection (Beijing Protocol vs PTCy), conditioning intensity, and supportive care protocols all affect outcomes. Seeking a second opinion from a high-volume haploidentical centre is appropriate before finalising a donor strategy.
Why Chinese Haematology Centres Are Particularly Relevant for Donor Shortage Cases
China's transplant programme has developed specifically around the reality of donor shortage. With smaller family sizes and a larger proportion of transplant candidates from ethnic backgrounds underrepresented in international registries, Chinese haematology centres were, by necessity, early leaders in developing robust haploidentical transplant protocols.
The world's largest haploidentical transplant cohort
Chinese centres — led by Peking University Institute of Haematology — have published the most extensive outcomes data on haploidentical transplant for a wide range of indications, including paediatric leukaemia, aplastic anaemia, thalassaemia, Fanconi anaemia, and adult malignancies. This volume of published evidence is not available anywhere else.
Haploidentical transplant as a primary strategy, not a fallback
In Chinese paediatric transplant practice, haploidentical donors now account for 56% of all cases nationally — more than matched sibling and matched unrelated donors combined. This is not because unrelated donors are never available, but because the haploidentical approach has been validated to the point where it is offered as a primary option when family donors are available.
Combined graft innovation
The combined haplo+cord blood strategy — using haploidentical PBSC for rapid engraftment alongside a cord blood unit for immune reconstitution — was developed in China and is used in approximately two-thirds of haploidentical PBSC transplants nationally. This innovation directly addresses some of the limitations of both pure haploidentical and pure cord blood approaches.
Structured remote evaluation
For families outside China who need to evaluate whether haploidentical or alternative donor transplant in China is appropriate, the process begins with an online MDT consultation — a structured remote review of existing records. This does not require travel and does not commit the family to any decision.
For families in this situation, the Pediatric Leukemia & Blood Disorders resource hub provides further context on how Chinese centres approach complex paediatric haematology cases.
Supportive Care During the Donor Search and Pre-Transplant Period
The period between a failed donor search and the initiation of transplant — often weeks to months — is itself a medically significant phase. For patients requiring ongoing disease control, bridging therapy must be managed carefully to maintain transplant eligibility without adding excessive toxicity.
At Chinese haematology centres, supportive care during the pre-transplant and peri-transplant period may include integrative approaches alongside standard haematological management — including acupuncture and traditional Chinese medicine (TCM) for fatigue, sleep, and quality-of-life support during intensive treatment. These are positioned as complementary to, not replacements for, the primary disease-directed treatment.
See the supportive care and Traditional Chinese Medicine resources for more information on what integrative care during cancer treatment in China may involve.
Related Guides
Haploidentical Transplant in China: When There Is No Matched Donor
The full haploidentical transplant resource hub — covering the Beijing Protocol, parent donor options, and donor shortage pathways.
What Families Should Know Before Pediatric Bone Marrow Transplantation
Donor types, the transplant timeline, GvHD explained in plain language, and questions to ask before agreeing to proceed.
Why Families Consider China for Complex Blood Disorders
The five specific clinical situations — including donor shortage — that lead international families to seek specialist blood disorder care in China.
Frequently Asked Questions
What does it mean when no matched unrelated donor is found?
A matched unrelated donor (MUD) is an individual found through a public stem cell registry (such as DKMS, NMDP/Be The Match, or Anthony Nolan) who shares a sufficient number of HLA antigens with the patient. If no such donor is identified — because of the patient's HLA type, ethnic background, or the urgency of the situation — this is reported as "no matched unrelated donor available." It does not mean no transplant is possible; it means the strategy shifts to alternative donor options.
Can a parent always donate stem cells to their child?
Biologically, every parent is a haploidentical (half-matched) donor for their child — sharing approximately 50% of HLA antigens. A parent donor is therefore almost always available. Whether a parent is medically suitable to donate depends on their own health, age, and fitness — which is assessed as part of the donor evaluation process. Parental haploidentical donation is now a primary transplant strategy rather than a last resort.
Is haploidentical transplant less effective than a matched unrelated donor transplant?
For many indications, modern haploidentical transplant using established protocols achieves outcomes comparable to matched unrelated donor transplant. Several prospective studies and registry analyses have demonstrated similar overall survival, disease-free survival, and rates of GvHD across donor types for conditions including acute leukaemia, aplastic anaemia, and thalassaemia. The specific protocol used, disease status at transplant, and centre experience all significantly influence outcomes — more so than donor type alone.
How long does an unrelated donor search typically take?
A comprehensive unrelated donor search through international registries typically takes three to six months from initiation to donor confirmation and harvest. This timeline may not be clinically acceptable for patients with rapidly progressive or relapsed disease. In these situations, proceeding with a haploidentical family donor — who is immediately available — may be preferred to waiting for a registry search outcome.
What is the first step for a family told no matched donor is available?
An online MDT consultation is the appropriate first step. It allows a specialist transplant team to review the patient's records, evaluate the family as potential haploidentical donors, assess whether cord blood or other alternatives are relevant, and provide a concrete recommendation — without requiring the family to travel first. This review can clarify which donor strategy is most appropriate for the specific diagnosis, disease status, and urgency of the situation.
Medical disclaimer
ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All donor selection and transplant planning decisions must be made by qualified haematologists and transplant physicians who have reviewed the patient's complete clinical records, HLA typing, disease status, and treatment history.
Get a specialist assessment of your donor options
An online MDT consultation with a Chinese haematology and transplant team reviews existing records, evaluates family as potential haploidentical donors, and gives a concrete recommendation on donor strategy — without requiring travel first.
Request a case reviewFor donor shortage, relapse, rare blood disorders, and complex haematology cases — no travel required to get started.